Herantis Pharma PLC · OMXHEX:HRTIS

Herantis Pharma — Technical Presentation (February 2020)

23 slides from Herantis Pharma's technical presentation, Feb 28, 2020

  1. Slide 1: Topline data on first 6 months of Phase 1-2 clinical study with CDNF

    Aiming at a breakthrough in Parkinson’s: Topline data on first 6 months of Phase 1-2 clinical study with CDNF Webinar 28 Feb 2020 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

  2. Slide 2: Disclaimer

    Disclaimer • This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc (‘Company’). The information provided in this presentation shall not be considered sufficient for making any investment decisions related to the Company. Anyone considering an investment in

  3. Slide 3: Topics of the webinar

    Topics of the webinar • Webinar practicalities • Introduction to CDNF as a potential Parkinson’s therapy • Phase 1-2 clinical study: design, dose groups, and demographics • Safety summary • Exploratory endpoint: DAT PET • Conclusions and questions by the audience 3 www.herantis.com © 2014-2020 HERAN

  4. Slide 4: Webinar practicalities

    Webinar practicalities: Estimated duration < 30 mins Henri Pekka • Speakers: Pekka Simula (CEO), Dr. Henri Huttunen (CSO) • This presentation will be available on Herantis web site → News & Events / Public materials • Questions have been received beforehand • Please note that the clinical study is s

  5. Slide 5: Neuroprotective factor CDNF aiming to stop the progression of Parkinson's disease

    Neuroprotective factor CDNF aiming to stop the progression of Parkinson’s disease (PD) 2/28/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

  6. Slide 6: CDNF aims at true disease modification

    CDNF aims at true disease modification • Available PD therapies such as levodopa only alleviate motor symptoms • There are no disease-modifying treatments • CDNF targets at a significant breakthrough in Parkinson’s disease by helping the dopaminergic neurons survive and recover, which could stop dis

  7. Slide 7: CDNF is a natural protein that helps our neurons survive

    CDNF is a natural protein that helps our neurons survive • Promising preclinical data in several neurological diseases → CDNF functions via several mechanisms relevant to PD and other neuro- degenerative diseases • Despite its name CDNF is very distinct from conventional neurotrophic factors such as

  8. Slide 8: Intraputamenal CDNF infusions in Parkinson's disease

    Intraputamenal CDNF infusions in Parkinson’s disease • PD is caused by the death of dopaminergic neurons of the nigrostriatal pathway → Reduced striatal dopamine levels → Motor symptoms • Based on preclinical data: Putamen → CDNF promotes functional recovery of dopaminergic terminals in the putamen

  9. Slide 9: Phase 1-2 clinical study: design, dose groups, demographics

    Phase 1-2 clinical study: design, dose groups, demographics www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

  10. Slide 10: Clinical study design: Three groups, three parts

    Clinical study design: Three groups, three parts Main Study (blinded) Extension Study Follow-Up Study 6 months 6 months 4 years Lower CDNF dose group (N=6) Higher CDNF dose group Monthly CDNF dosing Safety follow-up (N=5) All patients All patients Placebo dose group (N=6) Unblinding Feb 2020 • This

  11. Slide 11: Study is conducted at leading Nordic hospitals

    Study is conducted at leading Nordic hospitals Important to keep in mind when assessing the Main Study results: • First-in-human study with CDNF à primary endpoint is safety • Patients have an advanced PD à suboptimal patients for neuroprotective CDNF with significant loss of dopaminergic neurons •

  12. Slide 12: Demographic and PD characteristic data at screening

    Demographic and PD characteristic data at screening Characteristic Placebo CDNF (low-mid-mid) CDNF (low-mid-high) Age (years) 63.8 ± 6.4 63.2 ± 8.9 57.8 ± 6.7 Male sex, n (%) 5 (83.3%) 3 (50%) 4 (80%) White race, n (%) 6 (100%) 6 (100%) 5 (100%) Hoehn & Yahr (OFF), n (%) Stage 2 4 (66.7%) 3 (50%) 2

  13. Slide 13: Safety summary

    Safety summary 13 2/28/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

  14. Slide 14: Safety: The most common study drug-associated AEs

    Safety: The most common study drug-associated AEs • 39 adverse events (AE) possibly or probably related to CDNF were recorded in the Main study, experienced by at least two subjects Study drug-related AEs experienced by at least two Intensity Outcome TOTAL (n=17) patients NERVOUS SYSTEM DISORDERS #

  15. Slide 15: Safety summary after Main Study

    Safety summary after Main Study • Similar safety profiles in the placebo group and the two CDNF dose groups → Current data suggest CDNF is safe and well tolerated by patients with advanced PD → The main study met its primary endpoint on safety and tolerability of CDNF • Certain Serious Adverse Event

  16. Slide 16: Exploratory endpoint: DAT PET

    Exploratory endpoint: DAT PET 16 2/28/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

  17. Slide 17: Imaging of dopamine transporter activity in the brain

    Imaging of dopamine transporter activity in the brain • Dopamine transporter (DAT) is a presynaptic membrane protein which has a major role in the regulation of extracellular dopamine levels → DAT is enriched in nigrostriatal axons and terminals • In Parkinson disease, DAT is a useful biomarker for

  18. Slide 18: Exploratory outcome measures: DAT PET at 6 months

    Exploratory outcome measures: DAT PET at 6 months • DAT PET signal in the putamen between Baseline Baseline End of Main study and End of Main study (6 months): PET PET → Decrease in average DAT binding potential in placebo and in one CDNF group (-6-21%) → Increase in average DAT binding potential in

  19. Slide 19: Conclusions

    Conclusions 19 2/28/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

  20. Slide 20: Conclusions

    Conclusions • Primary endpoint met: CDNF is safe and well tolerated in advanced PD patients → These are patients who have lost most of their dopaminergic neurons; therefore, not optimal patients for the neuroprotective and neurorestorative CDNF • In PET imaging after 6 months, two patients show sign

  21. Slide 21: Questions received from the audience, page 1

    Questions received from the audience, page 1 • I have Parkinson’s disease. Can I volunteer for CDNF therapy? → Clinical development is strictly regulated. That applies to all new therapeutics-in- development, not just CDNF. We will keep our web site updated on future clinical studies. Please be pati

  22. Slide 22: Questions received from the audience, page 2

    Questions received from the audience, page 2 • Why were effects of CDNF not seen in every patient? → This is a first-in-human study with CDNF. The primary endpoint in first-in-human studies is always safety; typically you don’t expect any efficacy signals in Phase 1. In this case: • PD patients in t

  23. Slide 23: Thank you

    Thank you Further information: CEO Pekka Simula E-mail: pekka.simula@herantis.com Direct: +358 40 7300 445 2323 2/28/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

Herantis Pharma — Technical Presentation (February 2020) on 6ix